GSTM1 and urinary bladder carcinoma: In the well-characterized region of GSTM1, we found that PennCNV did not detect any deletion in a large sample of cases with bladder cancer and controls where homozygous deletion was known to have a frequency of 50% using Taqman and MLPA technologies.